Search Results - "Aotani, Eriko"

Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) – Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS) by Roncolato, Felicia T., Berton-Rigaud, Dominique, O'Connell, Rachel, Lanceley, Anne, Sehouli, Jalid, Buizen, Luke, Okamoto, Aikou, Aotani, Eriko, Lorusso, Domenica, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan, Hilpert, Felix, Ledermann, Jonathan A., Kaminsky, Marie Christine, Stockler, Martin R., King, Madeleine T., Friedlander, Michael

“…Modified Glasgow Prognostic Score (mGPS) is predictive of survival in many advanced cancers, but has not been evaluated in recurrent ovarian cancer (ROC). The…”
Get full text

Principle and evolving role of intraperitoneal chemotherapy in ovarian cancer by Fujiwara, Keiichi, Nagao, Shoji, Aotani, Eriko, Hasegawa, Kosei

“…Intraperitoneal (i.p.) chemotherapy has been extensively studied in the ovarian cancer field. Despite the fact that three large randomized trials that were…”
Get more information

Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer by Aotani, Eriko, Hamano, Tetsutaro, Gemma, Akihiko, Takeuchi, Masahiro, Takebayashi, Toru, Kobayashi, Kunihiko

“…Purpose In the CATS (Cisplatin And TS-1) randomized trial comparing cisplatin plus either docetaxel (DP arm) or TS-1 (SP arm) in lung cancer, efficacy was…”
Get full text

A randomized Phase II/III trial of 3 weekly intraperitoneal versus intravenous carboplatin in combination with intravenous weekly dose-dense paclitaxel for newly diagnosed ovarian, fallopian tube and primary peritoneal cancer by Fujiwara, Keiichi, Aotani, Eriko, Hamano, Tetsutaro, Nagao, Shoji, Yoshikawa, Hiroyuki, Sugiyama, Toru, Kigawa, Junzo, Aoki, Daisuke, Katsumata, Noriyuki, Takeuchi, Masahiro, Suzuki, Mitsuaki

“…Retrospective studies and a Phase II trial demonstrated the promising efficacy and safety of intraperitoneal administration of carboplatin in ovarian,…”
Get full text

International clinical trials: perspectives of clinical research coordinators by Aotani, Eriko

“…There are several different task roles among the co-medicals who are involved in international clinical trials (ICTs). In this review article, several issues…”
Get more information

Current movement in global clinical trials--discussion at Gynecologic Cancer Intergroup (GCIG) by Sagae, Satoru, Aoki, Daisuke, Susumu, Nobuyuki, Okamoto, Aikou, Aotani, Eriko, Takeuchi, Masahiro, Mandai, Masanori

Get more information

Randomized Phase III Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial by Sugiyama, Toru, Okamoto, Aikou, Enomoto, Takayuki, Hamano, Tetsutaro, Aotani, Eriko, Terao, Yasuhisa, Suzuki, Nao, Mikami, Mikio, Yaegashi, Nobuo, Kato, Kiyoko, Yoshikawa, Hiroyuki, Yokoyama, Yoshihito, Tanabe, Hiroshi, Nishino, Koji, Nomura, Hiroyuki, Kim, Jae-Weon, Kim, Byoung-Gie, Pignata, Sandro, Alexandre, Jerome, Green, John, Isonishi, Seiji, Terauchi, Fumitoshi, Fujiwara, Keiichi, Aoki, Daisuke

“…Clear cell carcinoma (CCC) is a rare histologic subtype that demonstrates poor outcomes in epithelial ovarian cancer. The Japanese Gynecologic Oncology Group…”
Get full text

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer by King, Madeleine T., Stockler, Martin R., O'Connell, Rachel L., Buizen, Luke, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Bryce, Jane, Donnellan, Paul, Oza, Amit, Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sehouli, Jalid, Feeney, Amanda, Berton-Rigaud, Dominique, Costa, Daniel S. J., Friedlander, Michael L.

“…Purpose Gynecologic Cancer Intergroup Symptom Benefit Study (GCIG-SBS) Stage 2 aimed to review, revise, and validate a patient-reported outcome measure (PROM),…”
Get full text

Reducing Uncertainty: Predictors of Stopping Chemotherapy Early and Shortened Survival Time in Platinum Resistant/Refractory Ovarian Cancer—The GCIG Symptom Benefit Study by Roncolato, Felicia T., Joly, Florence, O'Connell, Rachel, Lanceley, Anne, Hilpert, Felix, Buizen, Luke, Okamoto, Aikou, Aotani, Eriko, Pignata, Sandro, Donnellan, Paul, Oza, Amit, Avall‐Lundqvist, Elisabeth, Berek, Jonathan S., Heitz, Florian, Feeney, Amanda, Berton‐Rigaud, Dominique, Stockler, Martin R., King, Madeleine, Friedlander, Michael

“…Background Clinicians and patients often overestimate the benefits of chemotherapy, and overall survival (OS), in platinum resistant/refractory ovarian cancer…”
Get full text

How long have we got? The accuracy of physicians’ estimates and scenarios for survival time in 898 women with recurrent ovarian cancer (ROC) by Roncolato, Felicia, O'Connell, Rachel, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Pignata, Sandro, Donnellan, Paul P., Oza, Amit M., Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sehouli, Jalid, Ledermann, Jonathan A., Berton-Rigaud, Dominique, Kiely, Belinda Emma, Friedlander, Michael, Stockler, Martin R.

“…Abstract only 5549 Background: Predicting, formulating, and communicating prognosis in women with ROC is difficult. Best-case, worst-case, and typical…”
Get full text

Predictors of stopping chemotherapy early and short survival in patients with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) who have had ≥3 lines of prior chemotherapy: The GCIG symptom benefit study (SBS) by Roncolato, Felicia, Joly, Florence, O'Connell, Rachel, Lanceley, Anne, Heitz, Florian, Buizen, Luke, Okamoto, Aikou, Aotani, Eriko, Salutari, Vanda, Donnellan, Paul P., Oza, Amit M., Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Hilpert, Felix, Feeney, Amanda, Roemer-Becuwe, Celia, Stockler, Martin R., King, Madeleine Trudy, Friedlander, Michael

“…Abstract only 5575 Background: PPS ROC is defined by a platinum free interval > 6 months. Women starting ≥3 lines of chemotherapy for PPS ROC are however a…”
Get full text

Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS) by Roncolato, Felicia, O'Connell, Rachel, Buizen, Luke, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Pignata, Sandro, Donnellan, Paul P., Oza, Amit M., Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sjoquist, Katrin Marie, Gillies, Kim, Stockler, Martin R., King, Madeleine Trudy, Friedlander, Michael

“…Abstract only…”
Get full text

Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin—A Sankai Gynecology Study Group (SGSG) study by Miyagi, Yasunari, Fujiwara, Keiichi, Kigawa, Junzo, Itamochi, Hiroaki, Nagao, Shoji, Aotani, Eriko, Terakawa, Naoki, Kohno, Ichiro

“…To clarify the pharmacological advantage of carboplatin-based intraperitoneal chemotherapy using the three-compartment mathematical model. Eleven consecutive…”
Get full text

Phase II study of intraperitoneal carboplatin with intravenous paclitaxel in patients with suboptimal residual epithelial ovarian or primary peritoneal cancer: a Sankai Gynecology Cancer Study Group Study by Fujiwara, Keiichi, Nagao, Shoji, Kigawa, Junzo, Noma, Jun, Akamatsu, Nobuo, Miyagi, Yasunari, Numa, Fumitaka, Okada, Makoto, Aotani, Eriko

“…To assess the antitumor efficacy and safety of 2 treatment modalities: intraperitoneal carboplatin combined with intravenous (IV) paclitaxel. Eligible patients…”
Get more information

Baseline predictors of early treatment failure in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive (PPS ≥ 3) recurrent ovarian cancer (ROC) receiving ≥ 3 lines of chemotherapy: The Gynaecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS) by Roncolato, Felicia T, O'Connell, Rachel, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Pignata, Sandro, Donnellan, Paul P., Oza, Amit M., Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sjoquist, Katrin Marie, Gillies, Kim, Butow, Phyllis, Stockler, Martin R., King, Madeleine Trudy, Friedlander, Michael

“…Abstract only…”
Get full text

Is it time to change the primary endpoint in clinical trials in recurrent ovarian cancer (ROC)?: Symptom burden and outcomes in patients with platinum resistant/refractory (PRR) and potentially platinum sensitive ROC receiving ≥ 3 lines of chemotherapy (PPS ≥ 3)—The Gynecologic Cancer Intergroup (GCIG) Symptom Benefit Study (SBS) by Friedlander, Michael, Stockler, Martin R., O'Connell, Rachel, Joly, Florence, Lanceley, Anne, Hilpert, Felix, Okamoto, Aikou, Aotani, Eriko, Pignata, Sandro, Donnellan, Paul P., Oza, Amit M., Avall-Lundqvist, Elisabeth, Berek, Jonathan S., Sjoquist, Katrin Marie, Gillies, Kim, Butow, Phyllis, King, Madeleine Trudy

“…Abstract only…”
Get full text

First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up by Fujiwara, Keiichi, Sakuragi, Noriaki, Suzuki, Sachiko, Yoshida, Nobutaka, Maehata, Kenichiro, Nishiya, Masashi, Koshida, Takayuki, Sawai, Hideaki, Aotani, Eriko, Kohno, Ichiro

“…Currently, no long-term follow-up data are available on intraperitoneal (IP) carboplatin-based chemotherapy for ovarian carcinoma. In this study we evaluated…”
Get full text

Difference of carboplatin clearance estimated by the Cockroft–Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula by Nagao, Shoji, Fujiwara, Keiichi, Imafuku, Noriaki, Kagawa, Reina, Kozuka, Yoshiaki, Oda, Takashi, Maehata, Kenichiro, Ishikawa, Hiroyasu, Koike, Hirofumi, Aotani, Eriko, Kohno, Ichiro

“…Although the Calvert formula is the standard method to calculate the dose of carboplatin, there is no consensus how to determine the glomerular filtration rate…”
Get full text

A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer by Oishi, Tetsuro, Kigawa, Junzo, Fujiwara, Keiichi, Fujiwara, Michihisa, Numa, Fumitaka, Aotani, Eriko, Katsumata, Noriyuki, Kohno, Ichiro, Kato, Hiroshi, Terakawa, Naoki

“…A recent study demonstrated that docetaxel (DTX) was an effective agent for second line chemotherapy against ovarian cancer. Weekly administration of taxane…”
Get full text

Erratum to “First-line intraperitoneal carboplatin-based chemotherapy for 165 patients with epithelial ovarian carcinoma: results of long-term follow-up”: [Gynecol. Oncol. 90 (2003) 637–643] by Fujiwara, Keiichi, Sakuragi, Noriaki, Suzuki, Sachiko, Yoshida, Nobutaka, Maehata, Kenichiro, Nishiya, Masashi, Koshida, Takayuki, Sawai, Hideaki, Aotani, Eriko, Kohno, Ichiro

Get full text